ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Group 1 - The Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock from December 27, 2023, to May 6, 2025, about the lead plaintiff deadline on November 17, 2025 [1] - Investors who purchased Cytokinetics common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5] - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [5]